Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ambrose

Showing results (121-130 of 250) with videos related to

Pageof 25
Sort By:
Antimicrobial Agents and Chemotherapy|April 18, 2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populationsTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Environmental Pollution (Barking, Essex : 1987)|January 11, 2012
Persistent organic pollutants in four bivalve species from Svalbard watersIreen Vieweg, Haakon Hop, Thomas Brey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePaul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
Women & Health|February 6, 2019
Lower femoral neck bone mineral density (BMD) in elderly women not on statinsSimbo M Chiadika, Fisayomi O Shobayo, Syed H Naqvi, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremiaSujata M Bhavnani, Julie A Passarell, Joel S Owen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2013
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and AztreonamMichael N Dudley, Paul G Ambrose, Sujata M Bhavnani, et al.
The Pediatric Infectious Disease Journal|July 23, 2008
Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonateJohn S Bradley, Jason B Sauberan, Paul G Ambrose, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2023
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber <i>In Vitro</i> Infection ModelB D VanScoy, S Jones, H Conde, et al.
Ecotoxicology and Environmental Safety|January 26, 2016
Biological effects of mechanically and chemically dispersed oil on the Icelandic scallop (Chlamys islandica)Marianne Frantzen, Francesco Regoli, William G Ambrose, et al.
Pageof 25

Showing results (121-130 of 250) with videos related to

Sort By:
Pageof 25
Antimicrobial Agents and Chemotherapy|April 18, 2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populationsTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Environmental Pollution (Barking, Essex : 1987)|January 11, 2012
Persistent organic pollutants in four bivalve species from Svalbard watersIreen Vieweg, Haakon Hop, Thomas Brey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePaul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
Women & Health|February 6, 2019
Lower femoral neck bone mineral density (BMD) in elderly women not on statinsSimbo M Chiadika, Fisayomi O Shobayo, Syed H Naqvi, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremiaSujata M Bhavnani, Julie A Passarell, Joel S Owen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2013
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and AztreonamMichael N Dudley, Paul G Ambrose, Sujata M Bhavnani, et al.
The Pediatric Infectious Disease Journal|July 23, 2008
Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonateJohn S Bradley, Jason B Sauberan, Paul G Ambrose, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2023
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber <i>In Vitro</i> Infection ModelB D VanScoy, S Jones, H Conde, et al.
Ecotoxicology and Environmental Safety|January 26, 2016
Biological effects of mechanically and chemically dispersed oil on the Icelandic scallop (Chlamys islandica)Marianne Frantzen, Francesco Regoli, William G Ambrose, et al.
Pageof 25